Introduction {#sec1_1}
============

Papillary thyroid carcinoma (PTC) is the most common (80--85%) form of thyroid carcinoma and carries an excellent prognosis with the 25-year survival exceeding 95% \[[@B1], [@B2]\]. However, a subset of PTC patients will develop recurrent metastatic disease, with estimates of this population ranging from 15 to 30% \[[@B3], [@B4]\]. Half of such patients fail radioactive iodine (RAI), and systemic chemotherapy has minimal benefit in this clinical situation \[[@B3]\]. Multikinase small molecule inhibitors such as sorafenib and vandetanib can be used per recent NCCN guidelines (Version 2.2013), but prospective clinical trials have not yet demonstrated a distinct molecular subgroup of PTC patients that derives large benefit from such targeted therapies \[[@B5]\].

*BRAF* V600E is present in approximately 45% of all PTC \[[@B6]\], with alterations of *CTNNB1*, *HRAS*, *IDH1*, *KRAS*, *NRAS*, *PIK3CA* and *TP53* being less common. *BRAF* V600E is found more frequently in the classic and tall cell histologic variants \[[@B7]\] and is under investigation as a biomarker for diagnosis, prognosis and targeted treatment \[[@B8], [@B9]\]. For the latter, clinical trials are underway with vemurafenib as a treatment for metastatic PTC with *BRAF* V600E, and preliminary results are promising \[[@B10]\]. We report here a patient harboring *BRAF* V600E in her PTC as the sole somatic driver alteration identified by comprehensive genomic profiling by next-generation sequencing and with a durable antitumor response to vemurafenib.

Materials and Methods {#sec1_2}
=====================

Tissue from an incisional lymph node biopsy was submitted as a formalin-fixed, paraffin-embedded block to a CLIA-certified, CAP-accredited laboratory (Foundation Medicine, Cambridge, Mass., USA). The lymph node was selected for submission as this was the most recent and surgically accessible recurrent metastatic lesion. Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes frequently rearranged in cancer was applied to \>50 ng of DNA extracted from the block and sequenced to a median coverage of ×616 \[[@B11]\]. For thyroglobulin and antithyroglobulin testing, chemiluminescent immunoassays were performed.

Results {#sec1_3}
=======

In 2006, a 73-year-old woman with a prior history of early-stage breast cancer treated with lumpectomy, radiation and adjuvant tamoxifen presented with a neck mass at routine follow-up. Ultrasound evaluation of the neck showed a solid isoechoic mass contiguous with an enlarged left thyroid lobe with resulting right tracheal deviation. A CT scan showed four discrete neck masses, three on the left and one on the right. The primary nodule arising from the thyroid measured 4 by 3.2 cm and abutted the esophagus and the carotid sheath. The other lesions were felt most consistent with nodal metastases.

A fine-needle aspiration biopsy demonstrated a cytology characteristic of a papillary thyroid lesion. A thyroidectomy with bilateral modified radical neck dissection was performed, and pathologic examination identified a well-differentiated PTC, which measured 4.0 cm in greatest dimension (fig. [1a](#F1){ref-type="fig"}). Extrathyroidal extension and invasion of skeletal muscle and fat was present as well as multiple fused ipsilateral lymph nodes and contralateral nodes. The patient\'s disease was staged as T4N1bM0, stage IVa. I^131^ imaging revealed focal intense radioiodine uptake within the thyroid bed. The patient was treated with 200 mCi of I^131^ and placed on thyroid-stimulating hormone suppression.

In February 2012, the patient presented with progressive fatigue, dyspnea and neck fullness. A CT scan demonstrated innumerable pulmonary nodules, extensive mediastinal and hilar lymphadenopathy. A core needle biopsy of the lymph nodes demonstrated recurrence of well-differentiated PTC; dedifferentiation was not observed. Positron emission tomography (PET) imaging showed ^18^F-fluorodeoxyglucose-avid disease that extensively involved the base of the neck, mediastinum, pulmonary parenchyma and the pleura (fig. [2a](#F2){ref-type="fig"}).

I^131^ imaging showed residual uptake in the neck and diffuse disease within the lungs, cervical and mediastinal lymph nodes. A second course of I^131^ was administered, and PET imaging showed some regression of her neck lesion associated with mild improvement in respiratory symptoms, but the remainder of disease was unaffected (fig. [2b](#F2){ref-type="fig"}). Due to persistent dyspnea, additional therapeutic options were pursued. The patient\'s PTC underwent a comprehensive genomic profile and was identified as harboring *BRAF* V600E.

*BRAF* V600E was the sole genomic alteration identified in this specimen (fig. [1b](#F1){ref-type="fig"}), which did not contain tall cell features. This alteration occurred at a mutant allele frequency of 34% in the background of an estimated tumor content of 30%, as determined histologically. No focal high-level amplifications, small somatic insertions/deletions or rearrangements were present, and the tumor genome was estimated to be near diploid with trisomy 1q.

Risks and benefits were discussed, and the patient provided informed consent to proceed with vermurafenib treatment. She started with 960 mg of vemurafenib twice daily but experienced an extensive erythematous, pruritic rash. The treatment was briefly withheld and then resumed at 480 mg twice daily. The subsequent therapy was notable for a mild increase in bowel frequency; however, a significant improvement in dyspnea was observed. Two months later, repeat PET imaging demonstrated a dramatic reduction in both ^18^F-fluorodeoxyglucose avidity and mass size (fig. [2c](#F2){ref-type="fig"}) quantified as 76% by RECIST criteria and equally distributed over the pulmonary and nodal tissue. At 6 months, the patient continued to tolerate vemurafenib well, and subsequent imaging showed further improvement in disease burden (fig. [2d](#F2){ref-type="fig"}). In parallel, the patient\'s antithyroglobulin measurements decreased, although thyroglobulin was less informative and likely secondary to the high antithyroglobulin titer, which can interfere with assaying thyroglobulin levels (table [1](#T1){ref-type="table"}). She remains on therapy at 23 months and the disease is well controlled with few remaining symptoms attributable to her malignancy.

Discussion {#sec1_4}
==========

The mortality associated with PTC is concentrated in a subset of patients who develops recurrent, metastatic disease \[[@B2]\]. Treatment for such patients is dependent on the success of RAI, as systemic cytotoxic therapy is minimally effective. The substantial prevalence of *BRAF* V600E in PTC suggests potential responsiveness to treatment with vemurafenib, a small molecular kinase inhibitor known to be highly specific for *BRAF* V600E \[[@B12]\].

Clinical trials have demonstrated a subset of melanoma patients harboring *BRAF* V600E who respond well to vemurafenib treatment, leading to FDA approval of the drug. In contrast, patients with colon carcinoma containing the same alteration typically do not benefit from vemurafenib treatment \[[@B13]\]. The differential response between tumor types harboring *BRAF* V600E necessitates tumor-specific clinical investigations for assessing responsiveness to treatment with vemurafenib.

A recent phase I study of vemurafenib in patients with metastatic solid tumors reported responses from 3 patients with PTC harboring *BRAF* V600E \[[@B10]\]. After receiving 729 mg of vemurafenib on protocol, a retrospective molecular analysis of archived tumor tissue from these patients identified *BRAF* V600E in all of these samples, which is consistent with *BRAF* V600E present in 80% of the metastatic PTC patients. Two patients had stable disease, and the remaining patient had a partial response, as assessed by RECIST, with an average time to progression of 12.1 months \[[@B10]\]. Similarly, a phase II trial \[[@B14]\] treated 25 targeted therapy-naïve PTC patients with *BRAF* V600E with vemurafenib. Thirty-five percent of these patients had a partial response, and the mean progression-free survival was 15.6 months.

The targeted therapy-naïve patient described here received prospective genomic profiling that identified *BRAF* V600E as the only genomic alteration in a near diploid background. The lack of other driver alterations potentially suggests a strong reliance of tumor proliferation on *BRAF* V600E, a hypothesis that is supported by both the magnitude and duration (\>23 months and ongoing) of antitumor response to vemurafenib. This patient also did not experience squamous dysplasia on vemurafenib, in contrast to 2 of 3 patients in the phase I study \[[@B10]\]. It remains to be clarified whether both toxicity and the duration of the antitumor response can be linked to vemurafenib dosage, and whether the efficacy of the dosage is in turn dependent on the genomic profile of the tumor.

The exceptional antitumor response of this PTC patient with *BRAF* V600E suggests that a subset of patients may derive greater benefit from vemurafenib treatment, potentially with similar genomic profiles as the patient described herein. This therapeutic hypothesis should be investigated as clinicians caring for patients with metastatic RAI-refractory disease may consider utilizing genomic profiling.
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![**a** Histological section of a tumor metastatic to the lymph node, showing a papillary architecture and cytologic features of PTC (×200 magnification). **b** Next-generation sequencing demonstrating base substitution of c.1799 T\>A in *BRAF* at a mutant allele frequency of 34%, which gives rise to V600E.](cro-0007-0343-g01){#F1}

![Top panels are axial views of the thorax with CT imaging, and bottom panels are PET images. **a** Recurrent metastatic disease through the thorax. **b** After the second course of RAI treatment, to which the patient was refractory. **c** Two months after initiation of vemurafenib treatment. **d** Six months on vemurafenib treatment.](cro-0007-0343-g02){#F2}

###### 

Clinical events, thyroglobulin and antithyroglobulin levels

  Date        Event                        Thyroglobulin   Antithyroglob-ulin (Ab)
  ----------- ---------------------------- --------------- -------------------------
  6/9/2011                                 3.72            4,370
  4/2/2012                                 8.17            10,072
  4/9/2012    Second course of RAI                         
  5/8/2012    PET scan; limited response                   
  6/11/2012   Vemurafenib initiated                        
  1/21/2013                                5.28            1,962
  2/18/2013                                7.04            1,802
  6/18/2013                                3.21            820
  9/12/2013                                4.96            531

Chemiluminescent immunoassays were performed. Please note that thyroglobulin values could not be interpreted secondary to antibody interference.
